Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
GLAUKOS Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,589 shares of common stock to satisfy his tax withholding obligations.
After this non-market transaction, Thurman directly holds 43,681 shares of common stock. Footnotes also state he has 5,230 restricted stock units that have not yet vested or been delivered, indicating additional potential future equity awards.
GLAUKOS Corp president and COO Joseph E. Gilliam reported a routine tax-withholding share disposition tied to equity compensation. On the vesting and delivery of previously granted restricted stock units, 3,169 shares of common stock were withheld by the company at $109.60 per share to cover his tax obligations.
After this non-market transaction, he directly holds 92,992 shares of GLAUKOS common stock, including 43,925 restricted stock units that have not yet vested or been delivered. The filing does not reflect an open-market purchase or sale, but rather the automated tax treatment of stock-based compensation.
Glaukos Corp chairman and CEO Thomas William Burns reported non-market changes in his holdings. He transferred 180,308 shares of common stock as a bona fide gift from his direct ownership to the Burns Family Trust. Separately, a total of 9,937 shares were withheld by Glaukos at a price of $109.60 per share to satisfy his tax withholding obligations upon vesting and delivery of previously granted restricted stock units.
Following these transactions, Burns continues to hold common stock directly and indirectly through several trusts, and some of these positions include restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp Chief Development Officer Tomas Navratil reported a routine tax-withholding share disposition tied to restricted stock unit vesting. On March 31, 2026, 5,798 shares of common stock were withheld by the company at $109.60 per share to cover his tax obligations when RSUs granted on March 22, 2023 vested and were delivered. Following this withholding, he directly holds 95,440 shares, which includes 45,793 restricted stock units that are granted but have not yet vested or been delivered.
Glaukos Corp Chairman and CEO Thomas William Burns reported multiple equity compensation awards tied to performance goals. He received stock options covering 18,933 shares of common stock at an exercise price of $55.18 per share and 110,254 shares at $48.46 per share, reflecting portions of earlier performance-based grants that were earned after the board determined certain operational targets were achieved on March 25, 2026. He was also granted a new option for 98,474 shares at an exercise price of $109.60 per share, which vests over four years. In addition, he acquired 9,380 and 14,184 shares of common stock from performance-based restricted stock unit awards, with specified vesting in March and December 2026. Following these awards, he holds 263,271 common shares directly and maintains significant indirect holdings through various Burns family trusts.
Glaukos Corp SVP & CFO Alex R. Thurman reported a mix of equity awards and a small share sale. He sold 2,511 shares of common stock at $106.46 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. He received stock options for 8,228 shares at an exercise price of $55.18 expiring in 2032 and 20,515 shares at $109.60 expiring in 2036, along with other performance-based option portions that became earned after operational targets were achieved. He also acquired 3,303 shares of common stock from a performance-based restricted stock unit award. Following these transactions, he directly owns 45,270 shares of common stock, including unvested restricted stock units, indicating the sale is small relative to his overall equity position.
GLAUKOS Corp President & COO Joseph E. Gilliam reported a series of equity awards on March 25, 2026. He received stock options covering 16,462 and 21,955 shares of common stock at an exercise price of $55.18 per share and an additional option for 36,751 shares at $48.46 per share. He also was granted 5,829 and 17,792 shares of common stock as restricted stock unit-based awards. According to the footnotes, these grants were tied to the company’s achievement of multi-year operational and performance targets, with portions vesting in March and December 2026 and others vesting 25% annually over four years. These are compensation-related grants rather than open-market trades.
GLAUKOS Corp chief development officer Tomas Navratil reported several stock awards of common shares on March 25, 2026. The Form 4 shows multiple acquisitions coded as grants, with no purchase price, tied to previously granted restricted stock unit (RSU) awards.
These shares were earned after the board’s Compensation, Nominating and Governance Committee determined that specified multi-year operational performance targets from 2022, 2023, and 2024 RSU grants had been achieved. Following the latest grant entry, Navratil directly holds 101,238 common shares, and the footnotes state he also holds additional unvested RSUs, including 57,486 units that have not yet vested or been delivered.
Glaukos Corp ownership disclosure: The Vanguard Group filed an amendment on 03/13/2026 reporting 0 shares beneficially owned and 0% of the class following an internal realignment and separate reporting by subsidiaries.
The amendment states Vanguard subsidiaries will report beneficial ownership on a "disaggregated basis" in accordance with SEC Release No. 34-39538 (January 12, 1998). The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Glaukos Corp Chairman and CEO Thomas William Burns reported a tax-withholding share disposition related to equity compensation. On the vesting of previously granted restricted stock units, 2,744 shares of common stock were withheld by the company at $105.23 per share to cover his tax obligations. After this non-market transaction, he directly holds 239,707 common shares and also reports indirect ownership through several Burns family trusts. The filing also notes 59,399 restricted stock units that remain unvested and undelivered.